Lab
911 Labs INC
911 Labs INC was paid $4.56M by Medicaid between Dec 2022 and Jul 2024, across 6 billing codes. Its largest line is 87637, Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV — 84% of everything it billed.
33Billing provider info911 LABS INC
SANTA MONICA, CA 90401
SANTA MONICA, CA 90401
33aNPI1285360693assigned 07/27/2022
33bProvider typeClinical Medical Laboratory
28Total paid$4.56M
24GClaims49,551
24DCodes billed6
24AFirst – last monthDec 2022 – Jul 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#110 of 561
Median peer was paid$222K
This provider vs. median21×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 176 | $9K | |
| 2023 | 39,221 | $3.25M | |
| 2024incomplete | 10,154 | $1.30M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 84% | 29,971 | 19,518 | $3.84M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 6.4% | 4,807 | 3,005 | $292K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.1% | 2,251 | 1,483 | $139K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.7% | 2,686 | 1,830 | $122K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.4% | 6,180 | 3,825 | $107K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.3% | 3,656 | 1,941 | $59K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFARZAM, STEVE (COO)
| Provider | Location | Paid |
|---|---|---|
| 911Covidtesting INC | Santa Monica, CA | $152K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.